Color Code By Nicholas St. Fleur A ‘city on fire’: How Miami shaped a disputed diagnosis used to justify deaths in police custody
Biotech By Kate Sheridan When biotech acquisitions spike, early-stage startups are prime targets, analysis shows
Exclusive By Nicholas Florko Senate FDA legislation will include dietary supplement, cosmetic reforms
First Opinion By Michelle Collins and Cherie Burke The case of RaDonda Vaught highlights a double standard for nurses and physicians
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers
Biotech By Meghana Keshavan How global warming could help Martin Shkreli’s old company stay out of bankruptcy
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Pharma paid UK health care providers $450 million last year
Pharmalot By Ed Silverman A failed Valeant battlecry: ‘We’re not like Turing in any way, shape or form’
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Martin Shkreli may face more securities fraud charges
Business By Damian Garde Biotech bankruptcies, a trip to the Vatican, and Adam Feuerstein’s favorite bar
Pharmalot By Ed Silverman A family-run drug maker faces tough choices to stay afloat in the Shkreli era
Politics By Dylan Scott Drug sales dropped precipitously after Shkreli’s Turing hiked price, senator says
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Walgreens threatens to terminate Theranos partnership
Pharmalot By Ed Silverman Pharma industry has more in common with Martin Shkreli than it likes to admit
Politics By Rebecca Robbins and Dylan Scott Why Martin Shkreli reminds us so darn much of Donald Trump
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Amgen releases ‘secret’ data, AstraZeneca forecasts dip in profits